Literature DB >> 23816402

Historical perspective on effects and treatment of sulfur mustard injuries.

John S Graham1, Bruce A Schoneboom.   

Abstract

Sulfur mustard (2,2'-dichlorodiethyl sulfide; SM) is a potent vesicating chemical warfare agent that poses a continuing threat to both military and civilian populations. Significant SM injuries can take several months to heal, necessitate lengthy hospitalizations, and result in long-term complications affecting the skin, eyes, and lungs. This report summarizes initial and ongoing (chronic) clinical findings from SM casualties from the Iran-Iraq War (1980-1988), with an emphasis on cutaneous injury. In addition, we describe the cutaneous manifestations and treatment of several men recently and accidentally exposed to SM in the United States. Common, chronic cutaneous problems being reported in the Iranian casualties include pruritis (the primary complaint), burning, pain, redness, desquamation, hyperpigmentation, hypopigmentation, erythematous papular rash, xerosis, multiple cherry angiomas, atrophy, dermal scarring, hypertrophy, and sensitivity to mechanical injury with recurrent blistering and ulceration. Chronic ocular problems include keratitis, photophobia, persistent tearing, sensation of foreign body, corneal thinning and ulceration, vasculitis of the cornea and conjunctiva, and limbal stem cell deficiency. Chronic pulmonary problems include decreases in lung function, bronchitis with hyper-reactive airways, bronchiolitis, bronchiectasis, stenosis of the trachea and other large airways, emphysema, pulmonary fibrosis, decreased total lung capacity, and increased incidences of lung cancer, pulmonary infections, and tuberculosis. There are currently no standardized or optimized methods of casualty management; current treatment strategy consists of symptomatic management and is designed to relieve symptoms, prevent infections, and promote healing. New strategies are needed to provide for optimal and rapid healing, with the goals of (a) returning damaged tissue to optimal appearance and normal function in the shortest period of time, and (b) ameliorating chronic effects. Further experimental research and clinical trials will be needed to prevent or mitigate the acute clinical effects of SM exposure and to reduce or eliminate the long-term manifestations. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  1,1′-sulfonylbis[2-(methylthio)]ethane; AD; BMZ; Clinical signs and symptoms; Eyes; IFN-γ; LSCD; Lung; PTSD; SBMTE; SM; Skin; Sulfur mustard; TBSA; TDG; Treatments; atopic dermatitis; basement membrane zone; i.v.; interferon-gamma; intravenous; limbal stem cell deficiency; post-traumatic stress disorder; sulfur mustard; thiodiglycol; total body surface area

Mesh:

Substances:

Year:  2013        PMID: 23816402     DOI: 10.1016/j.cbi.2013.06.013

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  34 in total

1.  Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats.

Authors:  Matthew D McGraw; Marilyn M Dysart; Tara B Hendry-Hofer; Paul R Houin; Jaqueline S Rioux; Rhonda B Garlick; Joan E Loader; Russell Smith; Danielle C Paradiso; Wesley W Holmes; Dana R Anderson; Carl W White; Livia A Veress
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

2.  Acute corneal injury in rabbits following nitrogen mustard ocular exposure.

Authors:  Dinesh G Goswami; Rama Kant; David A Ammar; Dileep Kumar; Robert W Enzenauer; J Mark Petrash; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Exp Mol Pathol       Date:  2019-06-21       Impact factor: 3.362

Review 3.  The molecules in the corneal basement membrane zone affected by mustard exposure suggest potential therapies.

Authors:  Marion K Gordon; Andrea DeSantis-Rodrigues; Rita Hahn; Peihong Zhou; Yokechen Chang; Kathy K H Svoboda; Donald R Gerecke
Journal:  Ann N Y Acad Sci       Date:  2016-08       Impact factor: 5.691

Review 4.  Phosgene oxime: Injury and associated mechanisms compared to vesicating agents sulfur mustard and lewisite.

Authors:  Dinesh Giri Goswami; Rajesh Agarwal; Neera Tewari-Singh
Journal:  Toxicol Lett       Date:  2017-11-12       Impact factor: 4.372

5.  Expression of Laminin γ2 Proteolytic Fragments in Murine Skin Following Exposure to Sulfur Mustard.

Authors:  Yoke-Chen Chang; James D Wang; Hui-Ying Chang; Peihong Zhou; Rita A Hahn; Marion K Gordon; Jeffrey D Laskin; Donald R Gerecke
Journal:  Anat Rec (Hoboken)       Date:  2020-05-18       Impact factor: 2.064

Review 6.  Corneal toxicity induced by vesicating agents and effective treatment options.

Authors:  Dinesh G Goswami; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Ann N Y Acad Sci       Date:  2016-06-21       Impact factor: 5.691

7.  Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anti-inflammatory and anticholinergic bifunctional prodrug.

Authors:  Laurie B Joseph; Gabriella M Composto; Roberto M Perez; Hong-Duck Kim; Robert P Casillas; Ned D Heindel; Sherri C Young; Carl J Lacey; Jaya Saxena; Christophe D Guillon; Claire R Croutch; Jeffrey D Laskin; Diane E Heck
Journal:  Toxicol Lett       Date:  2017-11-07       Impact factor: 4.372

8.  Skin remodeling and wound healing in the Gottingen minipig following exposure to sulfur mustard.

Authors:  Jeffrey D Laskin; Gabriella Wahler; Claire R Croutch; Patrick J Sinko; Debra L Laskin; Diane E Heck; Laurie B Joseph
Journal:  Exp Mol Pathol       Date:  2020-05-21       Impact factor: 3.362

9.  TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation.

Authors:  Satyanarayana Achanta; Narendranath Reddy Chintagari; Marian Brackmann; Shrilatha Balakrishna; Sven-Eric Jordt
Journal:  Toxicol Lett       Date:  2018-03-10       Impact factor: 4.372

10.  Catalytic antioxidant AEOL 10150 treatment ameliorates sulfur mustard analog 2-chloroethyl ethyl sulfide-associated cutaneous toxic effects.

Authors:  Neera Tewari-Singh; Swetha Inturi; Anil K Jain; Chapla Agarwal; David J Orlicky; Carl W White; Rajesh Agarwal; Brian J Day
Journal:  Free Radic Biol Med       Date:  2014-05-09       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.